Recently, results from the Phase I/II LILACS trial (NCT03113773) reported that treatment of stable coronary artery disease patients with IL-2 safely expanded Tregs, with future studies now required to assess the clinical efficacy of this approach.69 Considering we find that abatacept also inhibits Tregs post-CIRI, these efforts raise a clear opportunity to improve T cell immunomodulation by also providing adjunct therapeutics like IL-2 to preserve the Treg response and maximize anti-inflammatory protection. The gene discussed is IL2; the disease is coronary artery disorder.